Description
MEXZOLE-LSR combines Esomeprazole Magnesium Trihydrate (E.C.) equivalent to Esomeprazole 40 mg with Levosulpiride (S.R.) 75 mg in a capsule formulation. Esomeprazole reduces gastric acid secretion, while Levosulpiride supports gastrointestinal motility. This combination is documented for short-term therapy of gastroesophageal reflux disease (GERD) in patients who do not respond adequately to proton pump inhibitor therapy alone.
For related gastrointestinal formulations and other pharmaceutical products, explore the Medhexa Pharma product range.
Therapeutic Segment
Gastrointestinal Care | GERD Management | Acid-Related Disorders | Proton Pump Inhibitors | Prokinetic Therapy
Uses of MEXZOLE-LSR
MEXZOLE-LSR may be prescribed for short-term management of gastroesophageal reflux disease (GERD) in patients who do not respond adequately to a proton pump inhibitor alone. The formulation combines acid suppression with gastrointestinal motility support.
Depending on the patient’s clinical condition, a healthcare professional may consider this combination for:
- Gastroesophageal reflux disease (GERD)
- Acid reflux and associated heartburn
- Acid-related upper gastrointestinal symptoms
- GERD that remains inadequately controlled with PPI therapy alone
- Selected gastrointestinal symptoms where combined acid suppression and prokinetic therapy are considered appropriate
The exact indication and treatment duration should always follow the prescribing healthcare professional’s assessment.
Key Benefits of MEXZOLE-LSR
MEXZOLE-LSR combines two active ingredients with complementary gastrointestinal actions:
- Esomeprazole 40 mg helps reduce gastric acid secretion.
- Levosulpiride 75 mg SR supports gastrointestinal motility.
- The formulation combines acid suppression with prokinetic support.
- Esomeprazole is provided as an enteric-coated formulation to protect the active ingredient from gastric acid.
- The sustained-release form of Levosulpiride supports its modified-release delivery.
- The capsule formulation allows convenient oral administration.
- Supplied in 10 × 10 ALU-ALU packaging.
CDSCO records the Esomeprazole 40 mg and Levosulpiride 75 mg combination for short-term GERD therapy in patients who do not respond to PPI therapy alone.
How MEXZOLE-LSR Works
Esomeprazole belongs to the proton pump inhibitor (PPI) class. It suppresses gastric acid secretion by specifically inhibiting the H⁺/K⁺-ATPase proton pump in gastric parietal cells. This blocks the final step of gastric acid production and reduces gastric acidity.
Levosulpiride acts primarily through dopamine receptor antagonism and can support gastrointestinal motility. This prokinetic action complements the acid-suppressing effect of Esomeprazole.
Therefore, MEXZOLE-LSR combines gastric acid suppression with gastrointestinal motility support.
Common Side Effects of MEXZOLE-LSR
Some patients may experience side effects while taking Esomeprazole or Levosulpiride.
Possible effects include:
- Headache
- Nausea
- Abdominal discomfort
- Diarrhea
- Constipation
- Flatulence
- Dizziness
- Dry mouth
- Fatigue
- Restlessness
Levosulpiride may also produce neurological or hormonal effects in some patients because of its dopamine-blocking activity.
If side effects persist, become severe or cause unusual symptoms, consult a healthcare professional.
Important Safety Information
MEXZOLE-LSR should be used only under the guidance of a qualified healthcare professional.
Before treatment, inform your healthcare professional about any history of:
- Movement disorders
- Seizures
- Gastrointestinal obstruction
- Gastrointestinal bleeding
- Significant liver disease
- Other neurological or gastrointestinal conditions
Levosulpiride may cause movement-related effects in susceptible individuals. Report unusual muscle movements, tremors, stiffness, severe restlessness or other abnormal neurological symptoms promptly.
Also inform your healthcare professional about all medicines and supplements you take. Medicines that affect dopamine pathways or the central nervous system may require additional consideration.
Esomeprazole can interact with certain medicines and can alter the absorption of medicines whose bioavailability depends on gastric acidity. Its prescribing information also highlights interactions involving medicines such as clopidogrel, methotrexate at high doses, rifampin and St. John’s wort.
Long-term PPI treatment may also be associated with risks such as vitamin B12 deficiency, hypomagnesemia and certain bone-related risks. Therefore, prolonged treatment should remain under appropriate medical supervision.
Patients with liver or kidney problems should inform their healthcare professional before using MEXZOLE-LSR.
Pregnant or breastfeeding patients should seek medical advice before taking this medicine.
Dosage & Administration
Take MEXZOLE-LSR exactly as prescribed by your healthcare professional.
The appropriate dose and duration depend on the patient’s condition, treatment response and the prescribing information applicable to the product.
Swallow the capsule whole with water. Do not crush or chew the enteric-coated or sustained-release components, as altering the dosage form may affect the intended release characteristics.
Esomeprazole is generally administered before meals according to the prescribing instructions. Follow the specific directions provided by the healthcare professional or product label.
Do not increase the dose, extend treatment or combine MEXZOLE-LSR with another Levosulpiride-containing medicine without medical advice.
Because CDSCO specifies this combination for short-term GERD therapy in patients who do not respond adequately to PPI therapy alone, treatment duration should follow professional medical advice.
Storage
Store MEXZOLE-LSR in a cool, dry place away from excessive heat, moisture and direct sunlight.
Keep the capsules in their original ALU-ALU packaging until use.
Follow the specific storage conditions printed on the product packaging.
Keep out of reach of children.
